Biotech · Private company
BioMed Valley Discoveries, Inc
Track this companyFree. Adds BioMed Valley Discoveries, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials135 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- BVD-523Phase 2 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BVD-523Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- HydroxychloroquinePhase 2 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
- Physician's ChoicePhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- UlixertinibPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- UlixertinibPhase 2 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
- Clostridium novyi-NT sporesPhase 1 · Solid Tumor MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisPHASE1_PHASE2 · RECRUITING · started Jan 7, 2025ClinicalTrials.gov NCT06773195 · fetched Nov 12, 2026
- Ulixertinib in People With Histiocytic NeoplasmsPHASE2 · RECRUITING · started May 7, 2024ClinicalTrials.gov NCT06411821 · fetched Nov 12, 2026
- Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyPHASE1 · RECRUITING · started Jan 18, 2024ClinicalTrials.gov NCT05985954 · fetched Nov 12, 2026
- Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated GliomasEARLY_PHASE1 · RECRUITING · started Apr 20, 2023ClinicalTrials.gov NCT05804227 · fetched Nov 12, 2026
- Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) MalignanciesPHASE2 · TERMINATED · started May 26, 2022ClinicalTrials.gov NCT05221320 · fetched Nov 12, 2026
- Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF AlterationsPHASE2 · TERMINATED · started Jan 7, 2021ClinicalTrials.gov NCT04488003 · fetched Nov 12, 2026
- Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal AdenocarcinomasPHASE1 · COMPLETED · started Mar 17, 2020ClinicalTrials.gov NCT04145297 · fetched Nov 12, 2026
- Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NTPHASE1 · COMPLETED · started Jul 10, 2018ClinicalTrials.gov NCT03435952 · fetched Nov 12, 2026
- A Phase II Study of BVD-523 in Metastatic Uveal MelanomaPHASE2 · TERMINATED · started Mar 26, 2018ClinicalTrials.gov NCT03417739 · fetched Nov 12, 2026
- Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsPHASE1 · RECRUITING · started Jan 30, 2018ClinicalTrials.gov NCT03454035 · fetched Nov 12, 2026
- Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromesPHASE1_PHASE2 · COMPLETED · started Nov 1, 2014ClinicalTrials.gov NCT02296242 · fetched Nov 12, 2026
- Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard TherapiesPHASE1 · COMPLETED · started Oct 1, 2013ClinicalTrials.gov NCT01924689 · fetched Nov 12, 2026
- Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced MalignanciesPHASE1_PHASE2 · COMPLETED · started Mar 1, 2013ClinicalTrials.gov NCT01781429 · fetched Nov 12, 2026